Call for tenders
“Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector” - 2017/RTD/E.1/OP/PP-06021-2017
(2017/S 150-309663)
Objectives and description
The Directorate General for Research and Innovation of the European Commission has
published a call for tenders for a “Study on the impact of mergers and
acquisitions on innovation in the pharmaceutical sector” -
2017/RTD/E.1/OP/PP-06021-2017.
One
of the challenges in the pharmaceutical and biotechnology sector is the
cost of developing new prescription medicinal products which has been
on the rise in the last 30-40 years, almost doubling every 10 years, and
reaching roughly $2.6 bn, according to one frequently quoted study.
With manifold reasons behind it, this trend poses challenges for the
continuous development of new treatments for patients' currently unmet
needs and for the long term sustainability of health systems. In this
context, industry players are in constant search of new efficiencies,
new medicinal products development models and additional revenues. Over
the last two decades a series of mergers and acquisitions (M&A) has
led to a consolidation in the pharmaceutical sector. The objective of
examining proposed mergers is to prevent harmful effects on competition,
thereby protecting consumer interests.
The main aim of this study is to understand
the impacts of mergers on innovation within the pharmaceutical sector.
The contractor will analyse at least 100 M&A cases from the period
2010–2013, looking at how different indicators evolve from 3-4 years
before merger until 3-4 years post-merger. Going beyond previous
academic works they will not only analyse R&D investment/intensity
and patents but indicators such as:
· number of drug candidates in various clinical development phases;
· progress in pipeline;
· number of discontinued programmes in view of related clinical trial results;
· market entry of new products.
Eligible activities
Tasks include:
· A statistical analysis of several indicators of merged companies and their competitors before and after the merger.
The
aim of this task is to complement earlier studies that examined
headline indicators such as R&D investment and patents, to obtain a
more complete picture of the impact of mergers not just on innovation as
a whole but also more specifically on medicinal products development
and launch.
· An in-depth quantitative and qualitative assessment of selected cases (case studies).
The
aim of the case studies is to illustrate and better understand the
effect of mergers on innovation and medicinal products development for
the relevant companies and for the given therapeutic segment and
distinguish this impact from other factors that could have influenced
innovation
Eligible participants - Minimum conditions
Natural and legal persons
from one of the EU Member States and all natural and legal persons in a
third country which has a special agreement with the European Union in
the field of public procurement on the conditions laid down in that
agreement.
Funding conditions and duration
The estimated value is 200 000.00 EUR excluding VAT and is not subject to renewal.
The maximum duration of the tasks is 12 months.
Deadline of proposals' submission
The deadline for submission of tenders is 29 September 2017.
You must submit your tender exclusively on paper, in one original and four copies.
Tenders must be submitted:
- Either by post. In this case the postmark will be proof of compliance with the deadline.
- Or by Courier. In this case the deposit slip of the courier office will constitute proof of compliance with the deadline.
- Or by Hand Delivery.
In this case Proof of receipt, signed and dated by the official in the
central mail department who takes delivery will constitute proof of
compliance with the deadline.
|
Post:
CALL FOR TENDERS
Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector - 2017/RTD/E.1/OP/PP-06021-2017
European Commission
Directorate-General for Research & Innovation], E.1, CDMA 2/173
For the attention of the Head of Unit
B – 1049 Brussels
Belgium
|
Courier services or Hand delivery:
CALL FOR TENDERS
Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector - 2017/RTD/E.1/OP/PP-06021-2017
European Commission
Directorate-General for Research & innovation, E.1, CDMA 2/173
For the attention of the Head of Unit
Avenue du Bourget 1
B-1140 Brussels (Evere)
Belgium
|
Further information
Please find attached the documentation of the call for tenders.
More information is available at the following link: https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798
Kind regards,
Flora
Flora Stavropoulou
Intern
European Office of Cyprus
Rue du Luxembourg 3, 2nd floor
B-1000, Brussels
Tel/Fax: +32 (0) 2 280 22 85
E-mail: eoc.brussels2@ucy.ac.cy
THE GREEK TRANSLATION IS AVAILABLE AT THE FOLLOWING LINK: https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798&locale=el
